Re: [MOL] tomaxafin [00274] Medicine On Line


[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

Re: [MOL] tomaxafin



Dear Jean:  Tamaxafin, has been proven to be ineffectual for the protection
against cancer after five year's, some new studdies around the world
indicate it is not effective after 17 months.  I am sending you some site to
go too that deal with this drug.  Good luck, your friend, lillian

http://www.nlm.nih.gov/databases/alerts/tamoxifen.html
http://www.nabco.org./index.html
http://www.oncolink.upenn.edu/upcc/clin_trials/sum95/tamox_ethics.html
httpwww.bca.ns.casurveysresults.htm


-----Original Message-----
From: Jean Jensen <violetj@webtv.net>
To: mol-cancer@meds.com <mol-cancer@meds.com>
Date: Tuesday, April 06, 1999 11:04 AM
Subject: [MOL] tomaxafin


Can anyone tell me if tomaxafin protects against breast cancer
recurrence beyond the 5 years it is prescribed for?

------------------------------------------------------------------------
This is an automatically-generated notice.  If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
majordomo@lists.meds.com
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email
address.
------------------------------------------------------------------------


------------------------------------------------------------------------
This is an automatically-generated notice.  If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
majordomo@lists.meds.com
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email
address.
------------------------------------------------------------------------